Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835198 · ClinicalTrials.gov registry record · Phase 4
Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
NCT00835198 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 163 participants.
The verdict
NCT00835198, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
Study Summary
A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tretinoin gel 0.025% compared with tretinoin gel 0.025% monotherapy in treating moderate to severe facial acne vulgaris
Interventions
- DRUG Tretinoin
- DRUG Dapsone; Tretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835198
The ClinicalTrials.gov registry entry for NCT00835198 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tretinoin is the first listed.
NCT00835198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835198 about?
NCT00835198 is a clinical study titled "Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris". A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tretinoin gel 0.025% compared with tretinoin gel 0.025% monotherapy in treating moderate to severe facial acne vulgaris
What is the current status of trial NCT00835198?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2008-12. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00835198?
The interventions under investigation include: Tretinoin (DRUG), Dapsone; Tretinoin (DRUG).
Who is sponsoring clinical trial NCT00835198?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.